Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of
this drug was documented in the BR. 21 trial showing that adenocarcinoma, female gender …

In order to evaluate the clinical efficacy and the safety profile of molecularly targeted
therapies as a palliative approach in elderly populations affected by advanced thoracic …

Background: As the incidence of lung cancer in the elderly is increasing worldwide, there
exists a need to develop a clinically effective, less toxic therapy for this patient population …

The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second‑or third‑line treatment for …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Purpose National Cancer Institute of Canada Clinical Trials Group Study BR. 21 established
erlotinib as a standard of care in patients with non–small-cell lung cancer (NSCLC) after …

There is no dedicated study on second-line treatment for elderly patients with advanced
nonsmall cell lung cancer (NSCLC). We report the results on second-line erlotinib therapy …

Abstract Tarceva Lung cancer Survival Treatment (TRUST) was an open-label, phase IV
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …

The incidence and mortality of lung cancer have increased worldwide over the last decades,
with an observed increased incidence particularly among elderly populations. It has not yet …

Non-small-cell lung cancer (NSCLC) predominantly occurs in the elderly, a group that has
been historically undertreated for various reasons such as perceived frailty and comorbidity …